Diversified design strategies for small-molecule PROTACs: How do we select?

Area of Science:

• Drug Discovery and Development
• Chemical Biology
• Medicinal Chemistry

Background:

• Proteolysis Targeting Chimeras (PROTACs) enable targeted protein degradation, revolutionizing drug discovery for previously undruggable targets.
• Traditional PROTACs face challenges including limited E3 ligase options, poor drug-like properties, and narrow target applicability, hindering clinical translation.

Purpose of the Study:

• To analyze and compare emerging PROTAC design strategies, including CHAMP, mini-PROTAC, covalent PROTAC, HyTTD, and pro-PROTAC.
• To provide guidance on selecting optimal PROTAC strategies based on target characteristics for enhanced clinical advancement.

Main Methods:

• Comprehensive review and analysis of recent advancements in PROTAC technology.
• Evaluation of strengths and limitations of various PROTAC design strategies, including E3 ligase-dependent/independent approaches and linker optimization.

Main Results:

• Emerging PROTAC strategies significantly enhance the technology's scope and clinical potential.
• Detailed analysis covers strategies for undruggable targets, E3 ligase utilization, and pro-PROTAC development.

Conclusions:

• The selection of an appropriate PROTAC strategy is crucial for successful drug development.
• Guidance is provided to facilitate the rational design and clinical translation of innovative PROTAC-based therapeutics.